Hedgepath, LLC Files Lawsuit Alleging Self-Dealing in Hedgepath

Pharmaceuticals, Inc. by Its Controlling Stockholder

Lawsuit alleges self-dealing in Hedgepath Pharmaceuticals, Inc. by its controlling stockholder, an

indirect subsidiary of Mayne Pharma Group Ltd. with estimated damages exceeding $800,000,000.

Tampa, FL, July 23, 2019 --(PR.com)-- Hedgepath, LLC (HPLLC), a development and financing
company for disruptive healthcare technologies, announced today that it has filed a lawsuit against the
Board of Directors of HedgePath Pharmaceuticals, Inc., (publicly traded on OTCQB exchange) its Chief
Executive Officer, and Mayne Pharma Ventures Pty Ltd. (Mayne) (publicly traded Australian company
on ASX exchange), which, allegedly, is HPPI's majority stockholder and a wholly-owned indirect
subsidiary of Mayne Pharma Group Limited. The lawsuit alleges that Mayne engaged in self-dealing by
using its control to acquire substantially all of the assets of HPPI for little or no consideration. HPLLC
alleges that damages exceed an estimated $800,000,000. The lawsuit, captioned Hedgepath, LLC v.
Magrab et al., C.A. No. 2019-0529-JTL, was filed in the Delaware Court of Chancery on July 9, 2019. A
public version of the Complaint, which redacts information designated as confidential by HPPI, has also
been filed with the Court.

Allegedly: HPLLC is the founder of HPPI and its largest minority stockholder, with beneficial ownership
of approximately 23.6% of HPPI's common stock; and HPLLC served as HPPI's sole initial investor, a
contributor of key intellectual property, the architect of the initial orphan cancer indication, and a
provider of expertise for the abbreviated 505(b)(2) regulatory pathway.

HPLLC alleges the lawsuit was filed after an inspection of corporate books and records pursuant to 8 Del.
C. § 220. The lawsuit alleges, among other things, a December 2018 agreement between HPPI and
Mayne, pursuant to which HPPI purported to transfer substantially all of its assets to Mayne for little or
no consideration; and without the requisite vote of stockholders and HPPI's Board of Directors.
Allegedly, the assets purportedly transferred to Mayne include HPPI's Investigational New Drug
Application, clinical data on the completed registration trial, and New Drug Application with the U.S.
Food and Drug Administration for an orphan hereditary cancer indication for which there is no approved
pharmaceutical, and the licensed intellectual property rights in the U.S. to approximately 98% of all
cancer indications. The lawsuit alleges that, by agreeing to the purported transfer, Mayne, HPPI's Board
of Directors, and HPPI's Chief Executive Officer breached their fiduciary duties to HPPI and its minority
stockholders and committed waste of corporate assets. The lawsuit also seeks a declaratory judgment that
the transactions contemplated by the alleged December 2018 agreement are void and unenforceable, and
asserts direct claims for breach of the duty of candor, fraudulent misrepresentations, and improper
dilution of stockholder equity associated with an alleged financing agreement between HPPI and Mayne.

Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
Hedgepath LLC
James A. McNulty, Manager HPLLC
813-864-2562
Contact via Email

Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/790211

Page 2/2
PR.com Press Release Distribution Terms of Use